Wednesday, November 14, 2012
ImmuneWorks Inc., of Indianapolis, said it completed a Phase I trial of Type V Collagen oral solution (IW001) in patients suffering from idiopathic pulmonary fibrosis. Thirty patients were enrolled in the 24-week study, which showed the drug to be well tolerated in preliminary results, with effects on lung function.
Sign up for Perspectives FREE e-mail newsletter.
Outside the U.S.: 1-404-262-5423
Hours: Monday - Thursday, 8:30 am - 6:00 pm EST
Friday, 8:30am - 4:30 pm EST
Copyright @ 2013 AHC Media. Reproduction, reposting content is strictly prohibited.